Low-grade serous carcinoma of the ovary or peritoneum

Area of Science:

• Gynecologic Oncology
• Translational Cancer Research
• Clinical Trial Design

Background:

• Epithelial cancers of the ovary, peritoneum, and fallopian tube have seen dramatic shifts in clinical trial strategies over the last decade.
• The NRG (GOG) Rare Tumor Committee has pioneered personalized approaches, moving away from uniform trial designs.
• Low-grade serous carcinoma (LGSC) is a distinct subtype with unique characteristics, including younger age at diagnosis, chemoresistance, and prolonged survival compared to high-grade serous carcinoma.

Purpose of the Study:

• To highlight the paradigm shift in clinical trial design for rare gynecologic cancers.
• To review the current understanding and therapeutic strategies for low-grade serous carcinoma.
• To emphasize the need for targeted therapy development in LGSC.

Main Methods:

• Review of clinical trial evolution and subtype-specific strategies.
• Analysis of pathological, molecular, and clinical behavior of LGSC.
• Summary of preclinical findings and clinical evidence for targeted agents.

Main Results:

• Conventional chemotherapy has shown limited efficacy in LGSC.
• Hormonal therapy may offer benefits for this subtype.
• Clinical evidence supports the activity of MEK inhibitors, BRAF inhibitors, and bevacizumab in LGSC.

Conclusions:

• Tailored clinical trials for rare gynecologic cancer subtypes are now standard.
• Targeted therapies, including MEK/BRAF inhibitors and bevacizumab, demonstrate clinical activity in LGSC.
• Further investigation and pursuit of targeted therapy trials are essential for advancing LGSC treatment.